Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium-224 labelled calcium carbonate microparticles
- Development stage
- Unknown
- Lead developer
- Oncoinvent
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
Radium-224 labelled calcium carbonate microparticles (Radspherin) is an investigational, receptor-independent, alpha-emitting radiopharmaceutical developed by Oncoinvent. It consists of biodegradable calcium carbonate (CaCO3) microparticles labeled with the alpha-emitting radionuclide radium-224 (224Ra). Administered intraperitoneally following cytoreductive surgery, the microparticles distribute throughout the peritoneal cavity, acting as a local depot that delivers short-range, high-energy alpha radiation to eradicate residual micrometastases and free-floating cancer cells while sparing surrounding healthy tissues. It is primarily being evaluated for the treatment of peritoneal carcinomatosis originating from ovarian and colorectal cancers.
- Brand names
- Radspherin
- Other names
- 224Ra-CaCO3-MP224Ra-CaCO3-MP-1Radium-224 RadSpherinRadium224 RadSpherinRadium 224 RadSpherinradium-224 calcium carbonate microparticlesradium224 calcium carbonate microparticlesradium 224 calcium carbonate microparticlesradium-224-labeled calcium carbonate microparticlesradium224-labeled calcium carbonate microparticlesradium 224-labeled calcium carbonate microparticlesradium-224-labelled calcium carbonate microparticlesradium224-labelled calcium carbonate microparticlesradium 224-labelled calcium carbonate microparticles
Beyond the preview
Go deeper on radium-224 labelled calcium carbonate microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium-224 labelled calcium carbonate microparticles.